Published online June 1, 2005
PEDIATRICS Vol. 115 No. 6 June 2005, pp. e749-e757 (doi:10.1542/peds.2004-2560)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow P3Rs: View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brown, R. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brown, R. T.
Related Collections
Right arrow Neurology & Psychiatry

TECHNICAL REPORT

Treatment of Attention-Deficit/Hyperactivity Disorder: Overview of the Evidence

Ronald T. Brown, PhD, Robert W. Amler, MD, Wendy S. Freeman, PhD, James M. Perrin, MD, Martin T. Stein, MD, Heidi M. Feldman, MD, PhD, Karen Pierce, MD, Mark L. Wolraich, MD and the Committee on Quality Improvement, Subcommittee on Attention-Deficit/Hyperactivity Disorder

ABSTRACT

The American Academy of Pediatrics' Committee on Quality Improvement, Subcommittee on Attention-Deficit/Hyperactivity Disorder, reviewed and analyzed the current literature for the purpose of developing an evidence-based clinical practice guideline for the treatment of the school-aged child with attention-deficit/hyperactivity disorder (ADHD). This review included several key reports, including an evidence review from the McMaster Evidence-Based Practice Center (supported by the Agency for Healthcare Research and Quality), a report from the Canadian Coordinating Office for Health Technology Assessment, the Multimodal Treatment for ADHD comparative clinical trial (supported by the National Institute of Mental Health), and supplemental reviews conducted by the subcommittee. These reviews provided substantial information about different treatments for ADHD and their efficacy in improving certain characteristics or outcomes for children with ADHD as well as adverse effects and benefits of multiple modes of treatment compared with single modes (eg, medication or behavior therapies alone). The reviews also compared the effects of different medications.

Other evidence documents the long-term nature of ADHD in children and its classification as a chronic condition, meriting the application of general concepts of chronic-condition management, including an individual treatment plan with a focus on ongoing parent and child education, management, and monitoring. The evidence strongly supports the use of stimulant medications for treating the core symptoms of children with ADHD and, to a lesser degree, for improving functioning. Behavior therapy alone has only limited effect on symptoms or functioning of children with ADHD, although combining behavior therapy with medication seems to improve functioning and may decrease the amount of (stimulant) medication needed. Comparison among stimulants (mainly methylphenidate and amphetamines) did not indicate that 1 class outperformed the other.

Key Words: attention-deficit hyperactivity disorder • stimulant medication • multimodal treatment • behavior management • co-occurring

Abbreviations: AAP, American Academy of Pediatrics • ADHD, attention-deficit/hyperactivity disorder • MTA, Multimodal Treatment Study for Children With ADHD • MPH, methylphenidate • DEX, dexedrine • PEM, pemoline • RCT, randomized, controlled trial




This article has been cited by other articles:


Home page
 J Child NeurolHome page
I. Berger, T. Dor, Y. Nevo, and G. Goldzweig
Attitudes Toward Attention-Deficit Hyperactivity Disorder (ADHD) Treatment: Parents' and Children's Perspectives
J Child Neurol, September 1, 2008; 23(9): 1036 - 1042.
[Abstract] [PDF]

Home page
 Learn. Mem.Home page
E. J. Dommett, E. L. Henderson, M. S. Westwell, and S. A. Greenfield
Methylphenidate amplifies long-term plasticity in the hippocampus via noradrenergic mechanisms
Learn. Mem., August 6, 2008; 15(8): 580 - 586.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
L. C. Krab, A. de Goede-Bolder, F. K. Aarsen, S. M. F. Pluijm, M. J. Bouman, J. N. van der Geest, M. Lequin, C. E. Catsman, W. F. M. Arts, S. A. Kushner, et al.
Effect of Simvastatin on Cognitive Functioning in Children With Neurofibromatosis Type 1: A Randomized Controlled Trial
JAMA, July 16, 2008; 300(3): 287 - 294.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
A. Kemp
Food additives and hyperactivity
BMJ, May 24, 2008; 336(7654): 1144 - 1144.
[Full Text] [PDF]

Home page
 J Atten DisordHome page
S. V. Faraone, J. Biederman, and B. Zimmerman
An Analysis of Patient Adherence to Treatment During a 1-Year, Open-label Study of OROS(R) Methylphenidate in Children With ADHD
J Atten Disord, September 1, 2007; 11(2): 157 - 166.
[Abstract] [PDF]

Home page
 FocusHome page
Bibliography PSYCHOPHARMACOLOGY
Focus, September 1, 2006; 4(4): 512.
[Full Text] [PDF]

Home page
 J PsychopharmacolHome page
H. Ashton, P. Gallagher, and B. Moore
The adult psychiatrist's dilemma: psychostimulant use in attention deficit/hyperactivity disorder
J Psychopharmacol, September 1, 2006; 20(5): 602 - 610.
[Abstract] [PDF]

Home page
 J Child NeurolHome page
L. Furman
What Is Attention-Deficit Hyperactivity Disorder (ADHD)?
J Child Neurol, December 1, 2005; 20(12): 994 - 1002.
[Abstract] [PDF]

P3Rs:

Read all P3Rs

Lack of empirical data for the treatment of up to half of the children with ADHD ignored
Joseph M. Rey
Pediatrics Online, 10 Jul 2005 [Full text]